 |
217 Diseases |  |
228 Trials |
|
228 Trials |  |
3892 News |  |
| «12...2122232425262728293031...4950» |
- || Halaven (eribulin mesylate) / Eisai
Clinical, Journal: A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient. (Pubmed Central) - Oct 7, 2020
After three surgical interventions, radiotherapy on the lesion of the penile bulb for satellite nodules and an epirubicin + ifosfamide chemotherapy treatment for six cycles, eribulin was administered at the dose of 1.1 mg/m on days 1 and 8, every 3 weeks for a total of nine cycles. A significant reduction of the lesions was achieved after four cycles of therapy, with a good profile of tolerability.
- | New P2/3 trial: Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer (clinicaltrials.gov) - Oct 5, 2020
P2/3, N=260, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- | epirubicin / Generic mfg.
Journal: Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway. (Pubmed Central) - Oct 3, 2020
A significant reduction of the lesions was achieved after four cycles of therapy, with a good profile of tolerability. Our results demonstrated that melatonin inactivates the NF-κB pathway and downregulates the expression of P-gp, ultimately sensitizing DLBCL cells to the epirubicin that suppresses their growth.
- paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Scenarios of Cost-Savings Associated with Oncotype DX® Test - Guided Decisions for Adjuvant Chemotherapy in EARLY Breast Cancer in Germany () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_187;
Testing and its associated reduction of chemotherapy use generates savings of €4,866,104 for 1,000 patients. CONCLUSIONS : Using Oncotype DX test for patients with early breast cancer provides a high potential to save costs for the German health-care system by guiding patients when to safely avoid adjuvant chemotherapy.
- || doxorubicin hydrochloride / Generic mfg.
Clinical, Retrospective data, Journal: Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. (Pubmed Central) - Oct 3, 2020
DSM-TACE of HCC is safe even in patients with advanced disease stages. Tumour response and survival rates were encouraging in our series of patients with locally extensive disease.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_1025;
The present study indicates the feasibility of CNA profiling by CUTseq and immuno-profiling by mfIHC in FFPE samples obtained from BC patients. Moreover, our data provide a link between genomic alterations and the immune landscape in early BC and set the basis for further application of CUTseq and mfIHC in larger patient cohorts.
- [VIRTUAL] Neoadjuvant adriamycin plus cyclophosphamide followed by docetaxel (AC4-D4) vs 5-fluorouracil, epirubicin plus cyclophosphamide followed by docetaxel (FEC3-D3) in stage II or III operable breast cancer : Randomized phase III neo-shorter trial (NCT02001506) (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_811;
P3
≥50% of baseline Ki-67 labeling index and ≥40% reduction of Ki-67 labeling index after NACT were independent for 3Y DFS. Shorter neo-adjuvant FEC3-D3 could be an alternative to AC4-D4 in stage II or III operable breast cancer.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_780;
P2
PEPI (PEPI II/II vs I: HR 0.80, 95%CI 0.18-3.67) and RCB scores (RCB II/III vs 0/I: HR 1.36; 95%CI 0.17-10.6) did not appear as independent predictors of PFS or iDFS. Conclusions Despite its small size, NeoPAL suggests that a neoadjuvant LETPAL strategy, together with selected postoperative administration of chemotherapy, may spare chemotherapy in some pts with luminal breast cancer while allowing very good long-term outcomes.
- pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
[VIRTUAL] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for stage I-III HER2-positive breast cancer: Results of a single-arm pilot clinical trial (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_764;
This pilot study initially reported that neoadjuvant therapy of P + EC-TH improved the tpCR rate in HER2-positive operable or locally advanced breast cancer by approximately one time higher than EC-TH neoadjuvant therapy reported in other trials, with tolerable side effects. A subsequent randomized phase III clinical trial is warranted.
- Herceptin (trastuzumab) / Roche
[VIRTUAL] Analysis of factors associated with pathological complete response (pCR) in patients with HER2+ breast cancer receiving neoadjuvant chemotherapy (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_715;
Our analysis suggests that for HER2+ breast cancers treated with NAC with anthracycline-taxane and trastuzumab, HER2 IHC 3+ expression is associated with a higher rate of pCR compared to HER2 IHC 2+ expression with FISH amplification. Further analysis in a larger cohort is warranted.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Prospective observational study of chemotherapy-induced alopecia after sequential FEC+taxane and the effects of age in breast cancer patients (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_633;
Severe CIA occurred in all 68 patients who received FEC and taxane chemotherapy. The present findings provide the first data demonstrating that age was not associated with the degree or incidence of hair loss, but age affected the recovery from CIA.
- Herceptin (trastuzumab) / Roche
[VIRTUAL] Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_379;
CelTIL score measured at week 2 of anti-HER2 therapy is significantly associated with long-term survival outcomes in early-stage HER2+ breast cancer, independently of pCR status and other prognostic variables. Further validation of this biomarker could help select early-on pts candidates for escalation or de-escalation of systemic therapy.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Androgen receptors are highly expressed in HER2-positive breast cancers that achieve pCR to anti-HER2 monoclonal antibodies (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_363;
P2
Then, they were randomly assigned (1:1) to receive: docetaxel (75 mg/m2) plus pertuzumab (840 mg loading dose (LD), then 420 mg) plus IV trastuzumab (8 mg/kg LD, then 6 mg/kg) q21 x 4 cycles (arm A) or, docetaxel plus pertuzumab plus SC trastuzumab (fixed dose of 600 mg) q21 x 4 cycles (arm B)...The higher AR expression observed in patients with pCR and high-sTILs suggests the combined use of TPCT with Selective Androgen Receptor Modulator (SARM). We are currently testing the in vitro combination of SARM with trastuzumab and pertuzumab, and efficacy results will be presented at the meeting.
- || cisplatin / Generic mfg., epirubicin / Generic mfg., gemcitabine / Generic mfg.
Clinical, Journal: Right supernumerary kidney with urothelial carcinoma: A case report. (Pubmed Central) - Oct 2, 2020
A supernumerary kidney is an extremely rare renal anomaly. Malignancy can occur in supernumerary kidneys.
- | cisplatin / Generic mfg., cyclophosphamide intravenous / Generic mfg., epirubicin / Generic mfg.
Journal: Distinct effects of epirubicin, cisplatin and cyclophosphamide on ovarian somatic cells of prepuberal ovaries. (Pubmed Central) - Oct 1, 2020
These results show that somatic cells of prepuberal ovary response to drugs in different ways, either undergoing apoptosis or SIPS, either showing resistance to Cisplatin and Phosphoramide Mustard. Moreover, a new role of LH in promoting DNA repair was shown.
- paclitaxel / Generic mfg.
[VIRTUAL] Locally advanced oesophageal cancer: a descriptive analysis to review outcomes of perioperative ECF chemotherapy vs neoadjuvant CROSS regime chemoradiotherapy at an Australian Regional Centre () - Sep 27, 2020 - Abstract #COSA2020COSA_249;
Perioperative ECF chemotherapy was previously used, comprising three 21-day cycles of epirubicin, cisplatin and flurouracil pre-surgery, then 3 cycles post...13% have relapsed. Conclusions : This is an ongoing project; further survival data to be elucidated.
- | epirubicin / Generic mfg.
Journal: Circulating Levels of Epirubicin Cause Endothelial Senescence While Compromising Metabolic Activity and Vascular Function. (Pubmed Central) - Sep 27, 2020
In vivo, epirubicin treatment resulted in persistent reduction in lung vascular density and significantly increased infiltration of myeloid cells. Modulation of endothelial status and inflammatory tissue microenvironment observed in response to low doses of epirubicin may predict risk for long-term secondary pathologies associated with chemotherapy.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer. (Pubmed Central) - Sep 26, 2020
These findings have important potential clinical implications for frontline regimen decision-making. We suggest there is warranted utility for prognostic PrPC/PRNP assays to guide chemo-sensitization strategies that exploit an understanding of PrPC-anthracycline-copper ion complexes.
- ||| cyclophosphamide intravenous / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal, Adverse events: Sarcopenia as a risk factor of severe laboratory adverse events in breast cancer patients receiving perioperative epirubicin plus cyclophosphamide therapy. (Pubmed Central) - Sep 26, 2020
Sarcopenia was a significant risk factor of severe laboratory toxicity in breast cancer patients receiving perioperative epirubicin plus cyclophosphamide therapy. This finding raises the potential use of body composition assessment to predict the risk of chemotherapy toxicity and determine an individualized treatment strategy.
- | epirubicin / Generic mfg.
Journal: Dual mode of binding of anti cancer drug epirubicin to G-quadruplex [d-(TTAGGGT)] containing human telomeric DNA sequence induces thermal stabilization. (Pubmed Central) - Sep 25, 2020
The specific interactions induce thermal stabilization of DNA by 13.2-26.3 °C, which is likely to come in the way of telomere association with telomerase enzyme and contribute to epirubicin-induced apoptosis in cancer cell lines. The findings pave the way for drug designing in view of the possibility of altering substituent groups on anthracyclines to enhance efficacy using alternate mechanism of its interaction with G4 DNA, causing interference in telomere maintenance pathway by inducing telomere dysfunction.
- || Clinical, Journal: Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. (Pubmed Central) - Sep 25, 2020
PCdd also yielded lower hematological toxicity. Thus, PCdd might be a preferred regimen for early TNBC patients with a high recurrence risk.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC) (Channel 1) - Sep 24, 2020 - Abstract #ESMOAsia2020ESMO_Asia_128;
P3
Methods Pts with previously untreated, nonmetastatic, centrally confirmed TNBC (T1c N1-2 or T2-4 N0-2 per AJCC) were randomized 2:1 to pembro 200 mg Q3W or pbo, both given with 4 cycles of paclitaxel + carboplatin, then 4 cycles of doxorubicin or epirubicin + cyclophosphamide (neoadjuvant phase)...Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT03036488.
- | epirubicin / Generic mfg.
Retrospective data, Journal: Standard-dose epirubicin increases the pathological complete response rate in neoadjuvant chemotherapy for breast cancer: a multicenter retrospective study. (Pubmed Central) - Sep 23, 2020
There was no significant difference in the incidence rates of grade III/IV adverse events between these two different dose groups. Standard-dose epirubicin increases the pCR rate in breast cancer patients treated with NAC, and no other toxicity is noted.
- | Journal: Development and validation of a LC-MS/MS quantification method of fourteen cytotoxic drugs in environmental samples. (Pubmed Central) - Sep 21, 2020
Standard-dose epirubicin increases the pCR rate in breast cancer patients treated with NAC, and no other toxicity is noted. This quantification method for 14 cytotoxic drugs was successfully applied to environmental contamination monitoring and could therefore be a useful tool for monitoring and toxicological studies.
- || epirubicin micelle formulation (NC-6300) / NanoCarrier, epirubicin / Generic mfg.
PK/PD data, Journal: Preparation and pharmacokinetics of bifunctional epirubicin-loaded micelles. (Pubmed Central) - Sep 21, 2020
The AUC calculated for the EPI-FIDCR formulation was 159.5-fold compared with that of EPI-Free, based on its improved stability and prolonged blood circulation time. The EPI-FIDCR enables both fluorescence imaging and controlled drug-release, exhibits prolonged systematic circulation time and has potential for the treatment of cancer.
- | Herceptin (trastuzumab) / Roche, epirubicin / Generic mfg.
Journal: HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor. (Pubmed Central) - Sep 19, 2020
8 h), deep tumor penetration, and superior tumor growth inhibition in SKOV-3 ovarian tumor bearing nude mice, which were more effective than free EPI•HCl and non-targeted Ps-EPI. These HER2-specific reduction-sensitive immunopolymersomes with high loading of epirubicin emerge as an attractive treatment for HER2-positive tumors.
- | epirubicin / Generic mfg.
Journal: Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. (Pubmed Central) - Sep 17, 2020
We also show that biological targeting, either through radiotherapy or EGFR, is critical to the therapeutic effects of nanoengagers. Last, EGFR-targeted nanoengagers can augment both NK-activating agents and chemotherapy (epirubicin) as highly effective anticancer agents, providing robust chemoimmunotherapy.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Down-regulation of FOS-like antigen 1 enhances drug sensitivity in breast cancer. (Pubmed Central) - Sep 16, 2020
Down-regulation of FOSL1 potentiated chemotherapy sensitivity of breast cancer, and its lower expression attenuated chemotherapeutic drug resistance in human breast cancer cells. FOSL1 might be a drug target for predicting chemotherapy effect in breast cancer.
- || cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting. (Pubmed Central) - Sep 13, 2020
FOSL1 might be a drug target for predicting chemotherapy effect in breast cancer. Combined aprepitant therapy is efficient and safe in the multiple-day anthracycline chemotherapy-induced nausea and vomiting control and is recommended for the clinical use.
- leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., paclitaxel / Generic mfg.
[VIRTUAL] Outcome of Locally Advanced Esophageal Cancer Patients Treated with Perioperative Chemotherapy and Chemoradiotherapy Followed by Surgery (Poster Hall) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_1801;
A trend towards improved recurrence-free survival in patients with CTRT compared to PCT. There was no difference in outcome between patients receiving 41 Gy versus 45 Gy or more.
- || cyclophosphamide intravenous / Generic mfg.
Clinical, Journal, HEOR: Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. (Pubmed Central) - Sep 12, 2020
There was no difference in outcome between patients receiving 41 Gy versus 45 Gy or more. To sum up, it would be necessary to make health professionals aware of the importance of chemotherapy-associated adverse reactions.
- | cyclophosphamide intravenous / Generic mfg., epirubicin / Generic mfg.
Journal: Complete atrioventricular block and torsade de pointes due to dose-dense epirubicin and cyclophosphamide therapy. (Pubmed Central) - Sep 10, 2020
A 12-lead ECG showed QT prolongation in addition to CAVB. Patients receiving dose-dense EC therapy should be monitored more carefully with ECG due to their risk of fatal arrhythmias.
- || epirubicin / Generic mfg.
PK/PD data, Journal: Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. (Pubmed Central) - Sep 9, 2020
Patients receiving dose-dense EC therapy should be monitored more carefully with ECG due to their risk of fatal arrhythmias. Conventional transarterial chemoembolization using the pumping emulsification device significantly improved the pharmacokinetics of epirubicin compared to the current standard technique using a 3-way stopcock.
- | epirubicin / Generic mfg.
Journal: Application of a combination of echocardiographic techniques in an experimental model of epirubicin-induced cardiotoxicity. (Pubmed Central) - Sep 8, 2020
GLS was the only predictor of cardiotoxicity. GLS combined with MPI may provide a noninvasive and accurate method for the early detection of cardiotoxicity.
- || paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy. (Pubmed Central) - Sep 5, 2020
Primary squamous cell carcinoma of the breast is a very rare disease with no standard treatment approach. Our case achieved pathologic complete response after neoadjuvant chemotherapy.
- | decitabine / Generic mfg.
Retrospective data, Journal: Decitabine Compared With Conventional Regimens in Older Patients With Acute Myeloid Leukemia: A Meta-Analysis. (Pubmed Central) - Sep 5, 2020
Our case achieved pathologic complete response after neoadjuvant chemotherapy. The findings presented in this article show that decitabine is effective and safe for the treatment of older patients with AML.
- | epirubicin / Generic mfg.
Journal: Transcriptional Suppression of the NLRP3 Inflammasome and Cytokine Release in Primary Macrophages by Low-Dose Anthracyclines. (Pubmed Central) - Sep 5, 2020
These anti-inflammatory effects were not mediated by the induction of autophagy or altered MAPK signaling, but as the result of a global transcriptional suppression of LPS-dependent genes. Epirubicin-treated macrophages displayed reduced acetylation of histone 3 lysine 9 (H3K9ac), suggesting anti-inflammatory epigenetic imprinting as one underlying mechanism.
- carboplatin / Generic mfg., paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Effectiveness and toxicity of carboplatin-containing neoadjuvant chemotherapy in patients with early triple negative breast cancer - a retrospective monocentric analysis (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_2177;
Out of them, 34 (19.4%) received a platin containing regimen (carboplatin group), most cases 21 (61.8%) in combination with paclitaxel followed by epirubicin and cyclophosphamide. With a good patient selection, carboplatin-containing neoadjuvant regimens can be safely applicated without increasing patients risk of discontinuing therapy or reducing dose intensity.
- cyclophosphamide intravenous / Generic mfg., epirubicin / Generic mfg.
[VIRTUAL] Relaxation training with a biofeedback device (QIU Ball) reduces the burden of symptoms in patients with early breast cancer during treatment with epirubicin and cyclophosphamide - a randomized study (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1814;
With a good patient selection, carboplatin-containing neoadjuvant regimens can be safely applicated without increasing patients risk of discontinuing therapy or reducing dose intensity. Relaxation training with the biofeedback device “Qiu ball” reduces symptom burden and its impact on daily living in patients with early breast cancer receiving (neo-) adjuvant treatment with Epirubicin and Cyclophosphamid.
- carboplatin / Generic mfg., paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Effectiveness and toxicity of carboplatin-containing neoadjuvant chemotherapy in patients with early triple negative breast cancer - a retrospective monocentric analysis (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1463;
Out of them, 34 (19.4%) received a platin containing regimen (carboplatin group), most cases 21 (61.8%) in combination with paclitaxel followed by epirubicin and cyclophosphamide. With a good patient selection, carboplatin-containing neoadjuvant regimens can be safely applicated without increasing patients risk of discontinuing therapy or reducing dose intensity.
- cyclophosphamide intravenous / Generic mfg., epirubicin / Generic mfg.
[VIRTUAL] Relaxation training with a biofeedback device (QIU Ball) reduces the burden of symptoms in patients with early breast cancer during treatment with epirubicin and cyclophosphamide - a randomized study (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1045;
With a good patient selection, carboplatin-containing neoadjuvant regimens can be safely applicated without increasing patients risk of discontinuing therapy or reducing dose intensity. Relaxation training with the biofeedback device “Qiu ball” reduces symptom burden and its impact on daily living in patients with early breast cancer receiving (neo-) adjuvant treatment with Epirubicin and Cyclophosphamid.
- carboplatin / Generic mfg., paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Effectiveness and toxicity of carboplatin-containing neoadjuvant chemotherapy in patients with early triple negative breast cancer - a retrospective monocentric analysis (Samarkand) - Sep 3, 2020 - Abstract #DGHO2020DGHO_808;
Out of them, 34 (19.4%) received a platin containing regimen (carboplatin group), most cases 21 (61.8%) in combination with paclitaxel followed by epirubicin and cyclophosphamide. With a good patient selection, carboplatin-containing neoadjuvant regimens can be safely applicated without increasing patients risk of discontinuing therapy or reducing dose intensity.
- carboplatin / Generic mfg., paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Effectiveness and toxicity of carboplatin-containing neoadjuvant chemotherapy in patients with early triple negative breast cancer - a retrospective monocentric analysis (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_669;
Out of them, 34 (19.4%) received a platin containing regimen (carboplatin group), most cases 21 (61.8%) in combination with paclitaxel followed by epirubicin and cyclophosphamide. With a good patient selection, carboplatin-containing neoadjuvant regimens can be safely applicated without increasing patients risk of discontinuing therapy or reducing dose intensity.
- cyclophosphamide intravenous / Generic mfg., epirubicin / Generic mfg.
[VIRTUAL] Relaxation training with a biofeedback device (QIU Ball) reduces the burden of symptoms in patients with early breast cancer during treatment with epirubicin and cyclophosphamide - a randomized study (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_229;
With a good patient selection, carboplatin-containing neoadjuvant regimens can be safely applicated without increasing patients risk of discontinuing therapy or reducing dose intensity. Relaxation training with the biofeedback device “Qiu ball” reduces symptom burden and its impact on daily living in patients with early breast cancer receiving (neo-) adjuvant treatment with Epirubicin and Cyclophosphamid.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Uncoupling DNA damage from chromatin damage to detoxify doxorubicin. (Pubmed Central) - Sep 2, 2020
The anthracycline doxorubicin (Doxo) and its analogs daunorubicin (Daun), epirubicin (Epi), and idarubicin (Ida) have been cornerstones of anticancer therapy for nearly five decades...Topo II poisons with either one of the activities fail to induce cardiotoxicity in mice and human cardiac microtissues, as observed for aclarubicin (Acla) and etoposide (Etop)...With these anthracyclines abstained from cardiotoxicity and therapy-related tumors, we thus uncoupled the side effects from anticancer efficacy. These results suggest that anthracycline variants acting primarily via chromatin damage may allow prolonged treatment of cancer patients and will improve the quality of life of cancer survivors.
- [VIRTUAL] KEYNOTE-522 Study of Pembro + Chemo vs. Placebo + Chemo as Neoadjuvant Treatment Followed by Pembro vs. Placebo as Adjuvant Treatment for Early TNBC: Pathologic Complete Response in Key Subgroups (ePoster Gallery) - Sep 1, 2020 - Abstract #SSO2020SSO_506;
P3
Pts were randomized 2:1 to the experimental and control arms to receive 4 cycles of [pembro (200mg Q3W) or pbo (normal saline)] + paclitaxel (80mg/m2 QW) + carboplatin (AUC 5 Q3W or AUC 1.5 QW) in the first 12 wks, followed by 4 cycles of pembro/pbo + [doxorubicin (60mg/m2 Q3W) or epirubicin (90mg/m2 Q3W)] + cyclophosphamide (600mg/m2 Q3W) in the subsequent 12 wks prior to surgery (neoadj part). pCR rates in key patient subgroups will be reported.
- oxaliplatin / Generic mfg., capecitabine / Generic mfg., epirubicin / Generic mfg.
[VIRTUAL] Early results of laparoscopic surgery for advanced adenocarcinoma of esophago-gastric junction (AEG) with neoadjuvant chemotherapy () - Sep 1, 2020 - Abstract #SAGES2020SAGES_1470;
LS is also benefit for those with peritoneal metastasis which was not detected before operation. Long term follow-up is neccesary to evaluate oncological results as well as quality of life of these patients.
- | epirubicin / Generic mfg.
Journal: Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma. (Pubmed Central) - Aug 30, 2020
However, the frequency of arterio-portal shunt formation was significantly higher in HCC patients with Child-Pugh class A undergoing DEB-TACE. Our findings imply that C-TACE should be selected for HCC patients with Child-Pugh class A and DEB-TACE should be chosen for those with Child-Pugh class B.
- | epirubicin / Generic mfg.
Journal: A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence. (Pubmed Central) - Aug 29, 2020
In contrast, knockdown of MED1 did not prevent development of B-Raf- and Epirubicin-induced senescence, suggesting that Mediator may be specifically linked to the cellular functions of SSX2 that may lead to development of senescence or be central in a SSX2-specific senescence response...Similarly, RNA-seq analysis suggested that MED1, MED4, and MED14 were downregulated in some tumors, while upregulated in others. In conclusion, our study reveals the Mediator complex as essential for SSX2-induced senescence and suggests that changes in Mediator activity could be instrumental for tumorigenesis.
- | epirubicin / Generic mfg.
Journal: A facile adenosine triphosphate-responsive nanoplatform for efficacious therapy of esophageal cancer. (Pubmed Central) - Aug 26, 2020
First, the chemotherapeutic agent epirubicin (EPI) was inserted into an ATP aptamer (Ap) to form double-stranded DNA ('DNA duplex')...In vitro cytotoxicity and apoptosis assays demonstrated that PEI-Ap-EPI could enhance EPI efficiency against EC cells markedly compared with those in the control group. Therefore, this facile PEI-Ap-EPI nanoplatform may be a promising strategy to improve the efficacy of EPI treatment in EC.